Search results
Results from the WOW.Com Content Network
The COVID-19 pandemic in Vietnam has resulted in 11,624,000 confirmed cases of COVID-19 and 43,206 deaths. The number of confirmed cases is the highest total in Southeast Asia , and the 13th highest in the world .
COVID-19 vaccination in Vietnam. 90,272,853 [3] people with at least one dose administered of COVID-19 vaccine. 85,961,564 [3] people have been fully vaccinated. 91.94 [3] percent of the Vietnamese population has received at least one dose. 87.55 [3] percent of the Vietnamese population is fully vaccinated.
2020-01-23: 2 (n.a.): 0 (n.a.): ⋮: 2 (=): 0 (n.a.): 2020-01-28: 2 (=): 0 (n.a.): ⋮: 2 (=): 0 (n.a.): 2020-01-31: 5 (+3): 0 (n.a.): 2020-02-01: 6 (+1): 0 (n.a ...
The government of Vietnam prepared for the COVID-19 pandemic as early as the first cases in China emerged in December 2019, and pursued a zero-COVID strategy until September 2021. In January 2020, Vietnam's Prime Minister Nguyễn Xuân Phúc ordered measures to prevent and counter the spread of the disease into Vietnam, [1] as well as to warn ...
The COVID-19 pandemic in Southeast Asia is part of the ongoing worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was confirmed to have spread to Southeast Asia on 13 January 2020, when a 61-year-old woman from Wuhan tested positive in Thailand , making it the ...
The COVID-19 pandemic began in Asia in Wuhan, Hubei, China, and has spread widely through the continent. As of 18 May 2024, at least one case of COVID-19 had been reported in every country in Asia except Turkmenistan. The Asian countries with the highest numbers of confirmed coronavirus cases are India, South Korea, Turkey, Vietnam, and Iran.
US: Crunchyroll Channel. Original run. January 8, 2020 – April 15, 2020. Episodes. 12. Number24 is a Japanese anime television series produced by PRA and directed by Shigeru Kimiya. It aired on Tokyo MX from January to April 2020.
The phase III study is the adaptive, multicenter, randomized, double-blind, placebo control study to evaluate the safety, immunogenicity, and efficacy of the Nanocovax vaccine against COVID-19 in volunteer subjects 18 years of age and older.